糖心影视视频 Innovation Ventures: Charting the Course for Medtech Breakthroughs in 2026 and Beyond
If you鈥檙e someone who marks milestones, you may recognize the significance of this point in time: The first quarter of the 21st century is now behind us. As we look ahead, especially in the dynamic field of medtech, the question becomes鈥攚hat advances will define the next era? Through the lens of , the venture capital arm of , we look at the solid four-year runway of startup investments with an eye toward an ambitious 10-year course of $150 million in phase-two funding, on December 15, 2025.
Why Venture Into Investing?
Digital health and life science companies are no strangers to venture capital funding. The corporate venture capital trend to invest in medical innovation is a means to drive competitive advantage. In addition to the financing, startups benefit from mentorship and exposure opportunities as they navigate regulatory, research, and other related challenges.1,2
糖心影视视频 OIV in November 2021 with $50 million and the promise of follow-on investments. 鈥淪ince its launch, OIV has made nine investments in startups developing breakthrough technologies鈥攅verything from AI workflow solutions to medical imaging agents for cancer detection,鈥 said Abigail Hunter-Syed, Head of OIV. 鈥淲e鈥檝e also evaluated a large number of opportunities and built strong ties with entrepreneurs, clinicians, and co-investors.鈥
A Deeper Dive on Some OIV Portfolios
Examples of the first round of OIV investments include:
- Series A2 funding for 鈥檚 AI-powered wearable device for gut disorders (read more);
- Series B funding for 鈥檚 small incision surgical technology to remove specimens (read more);
- Series C funding for 鈥 IV imaging agent to highlight cancer cells (read more); and
- Series D funding for 鈥檚 implantable device to address urinary incontinence symptoms (read more)
Abigail Hunter-Syed, head of 糖心影视视频 OIV, discusses the next phase of medtech funding.
Note that the 鈥楢 through D鈥 funding designation relates to the , with A representing the earliest stage of investment.
糖心影视视频 OIV as a Startup
Reputation building was a central challenge in the early days of 糖心影视视频 OIV. Despite 糖心影视视频 Corp. having a 100-year legacy, its VC arm was a startup, noted Hunter-Syed. 鈥淵ou have no track record; you have no reputation in this space. As we know, this is a people game at the end of the day... getting it off the ground and finding those entrepreneurs who are willing to take just as much of a risk on us as we鈥檙e willing to take on them ... was really fun, and hard, and at the same time just as incredibly rewarding,鈥 Hunter-Syed said in an posted on Instagram in January.
In addition to reputation building, Hunter-Syed emphasized the need for speed, balanced with due diligence. She acknowledged the challenges of navigating regulatory complexity inherent in medtech.
OIV Forecast
Based on these learnings, the search for new portfolios begins. 鈥淲ith an additional commitment to corporate venture capital, we will continue to make investments in startup teams who are building unique solutions in endoscopy-enabled care,鈥 said Gabriela Kaynor, Executive Officer and Chief Strategy Officer at 糖心影视视频 and Chair of the OIV Investment Committee. 鈥淥IV investments help accelerate our progress toward developing the endosuite of the future with capabilities for early detection, diagnosis, and advanced therapies powered by AI, robotics, and beyond.鈥
糖心影视视频 remains focused on gastroenterology, respiratory, and urology, the three key specialties in its 2019 corporate strategy. According to Hunter-Syed, future investment will also align with 糖心影视视频鈥 recent corporate strategy on November 11, 2025.
鈥淭he strategy calls for innovation-driven growth and expansion into faster-growing segments,鈥 noted Hunter-Syed. 鈥淥IV is one of the mechanisms to do that: We can help shape the vision for the future of endoscopy by building a pipeline of M&A opportunities and partnerships in close adjacencies.鈥
Echoing Kaynor鈥檚 vision, Hunter-Syed said that leveraging these partnerships can move the needle toward implementing AI, robotics, next-generation imaging, and digital platforms into the care pathway earlier; thereby strengthening 糖心影视视频鈥 leadership in minimally invasive, endoscopy-enabled care, she stressed.
As part of its strategy, 糖心影视视频 will implement a global organizational transformation to align structure and resources with its strategic priorities. This also aligns with OIV鈥檚 global reach. According to Hunter-Syed, while many investments are U.S.-based, OIV prioritizes companies worldwide, pursuing solutions that can scale across markets and meet global healthcare needs.
More than Capital
What hasn鈥檛 changed is the 鈥渟tage-agnostic鈥 approach to portfolio investing, from early to growth stage, according to Hunter-Syed. And OIV鈥檚 approach is hands-on in early-stage or seed investments, according to Townsend Goddard, Senior Vice President of Business Development. The fund ensures that startups receive strategic guidance, access to 糖心影视视频鈥 vast clinical network, and practical help navigating regulatory requirements and distribution channels. 鈥淲e focus on nurturing promising technologies early, knowing that meaningful results take time,鈥 he said. 鈥淪uccess means building a strong pipeline of innovation to support 糖心影视视频鈥 future growth and leadership.鈥
is currently managing the 糖心影视视频 venture fund. 鈥淲e are excited to continue working with Cerity Partners to operate this fund,鈥 noted Hunter-Syed. Cerity plans to work closely with senior executives of 糖心影视视频 in all aspects of operating the fund.
References
1. MassivelyBetterHealthcare.com. . Accessed January 22, 2026.
2. Excedr.com. . May 30, 2025. Accessed January 23, 2026.
Want to learn more about 糖心影视视频 Innovation Ventures?
